Effects of Two Compound Probiotic Formulations on Gastrointestinal Symptoms and Gut Microbiota: A 4-Week Randomized, Double-Blind Intervention Trial
Nutrients · 06.09.2025 · 17 (17) · 2886
DOI: 10.3390/nu17172886 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, online erschienen am 06.09.2025. Verfasst von Zhen Qu und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Food and Bioengineering, Henan University of Science and Technology, Luoyang 471000, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Probiotics, Gastrointestinal Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Major Science and Technology Special Projects in Henan Province, Key R&D Projects in Henan Province.
Abstract (Originalsprache)
Background/Objectives: Probiotic interventions can alleviate gastrointestinal (GI) discomfort, but evidence comparing multi-strain combinations at different doses remains limited. We evaluated whether formulation potency influences clinical and microbiome outcomes.
Methods
In a 4-week, randomized, double-blind trial, 100 eligible adults received one of two higher-dose multi-strain probiotic formulations at different dosages (Wec120B vs Wec300B). Weekly Gastrointestinal Symptom Rating Scale (GSRS) scores tracked symptom trajectories. Gut microbiota composition and diversity were profiled by 16S rRNA gene sequencing. Biomarkers included lipopolysaccharide (LPS), fecal calprotectin (FC), and immunoglobulin A (IgA).
Results
Results indicated that the Wec120B group showed more significant improvement in abdominal pain during the early phase of intervention, while the Wec300B group was more effective in relieving reflux symptoms. In terms of biomarkers, Wec120B was more effective in reducing lipopolysaccharide (LPS) levels, whereas Wec300B showed a greater increase in immunoglobulin A (IgA) and a more pronounced reduction in fecal calprotectin (FC) levels. Both formulations significantly increased the abundance of beneficial genera such as Bifidobacterium, Blautia, [Eubacterium]_hallii_group, and Anaerostipes, while suppressing the growth of potential pathogens including Prevotella and Escherichia-Shigella.
Conclusions
These findings suggest that both compound probiotic products can significantly improve GI symptoms and modulate gut microbiota structure, with Wec300B showing a superior performance in microbial regulation, likely due to its higher dosage of probiotics. This study provides reference evidence for the rational application of probiotic products in gut health management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Food and Bioengineering, Henan University of Science and Technology, Luoyang 471000, China.
- Henan Engineering Research Center of Food Material, Henan University of Science and Technology, Luoyang 471023, China.
- Wecare Probiotics R&D Centers (WPC), Wecare Probiotics Co., Ltd., Suzhou 215200, China.
- Henan Engineering Research Center of Food Microbiology, Luoyang 471000, China.
ORCID-Profile: Ying Wu
Förderung
- Major Science and Technology Special Projects in Henan Province
- Key R&D Projects in Henan Province
Zitieren
APA
Qu, Z., Wu, Y., Jiang, Y., Fan, J., Cao, L., Dong, Y., Fang, S., & Gu, S. (2025). Effects of Two Compound Probiotic Formulations on Gastrointestinal Symptoms and Gut Microbiota: A 4-Week Randomized, Double-Blind Intervention Trial. Nutrients, 17(17), 2886. https://doi.org/10.3390/nu17172886
Vancouver
Qu Z, Wu Y, Jiang Y, Fan J, Cao L, Dong Y, et al. Effects of Two Compound Probiotic Formulations on Gastrointestinal Symptoms and Gut Microbiota: A 4-Week Randomized, Double-Blind Intervention Trial. Nutrients. 2025;17(17):2886. doi:10.3390/nu17172886
BibTeX
@article{Qu2025,
author = {Qu, Zhen and Wu, Ying and Jiang, Yiru and Fan, Jiajia and Cao, Li and Dong, Yao and Fang, Shuguang and Gu, Shaobin},
title = {Effects of Two Compound Probiotic Formulations on Gastrointestinal Symptoms and Gut Microbiota: A 4-Week Randomized, Double-Blind Intervention Trial},
journal = {Nutrients},
year = {2025},
volume = {17},
number = {17},
pages = {2886},
doi = {10.3390/nu17172886}
}
EUVIMED